Page last updated: 2024-12-08
spinacine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
spinacine: structure given in first source; RN from Toxlit 4/88 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 162899 |
| CHEBI ID | 177618 |
| SCHEMBL ID | 3739922 |
| SCHEMBL ID | 10544160 |
| MeSH ID | M0155839 |
Synonyms (35)
| Synonym |
|---|
| (6s)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| CHEBI:177618 |
| 59981-63-4 |
| l-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| spinacine |
| AKOS006279535 |
| 1h-imidazo(4,5-c)pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-, (s)- |
| eg040ze63k , |
| unii-eg040ze63k |
| (s)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| AKOS016370682 |
| SCHEMBL3739922 |
| (s)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| SCHEMBL10544160 |
| 4,5,6,7-tetrahydro-3h-imidazo(4,5-c)pyridine-6.alpha.-carboxylic acid |
| (s)-4,5,6,7-tetrahydro-1h-imidazo(4,5-d)pyridine-6-carboxylic acid |
| 3h-imidazo(4,5-c)pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-, (6s)- |
| (s)-4,5,6,7-tetrahydro-1h-imidazo(4,5-c)pyridine-6-carboxylic acid |
| j20.474i , |
| (6s)-4,5,6,7-tetrahydro-3h-imidazo(4,5-c)pyridine-6-carboxylic acid |
| spinacin |
| (-)-spinacine |
| l-spinacine |
| DTXSID80208688 |
| mfcd01318776 |
| (6s)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| CS-0063803 |
| AS-41213 |
| mfcd11518850 |
| Q27277160 |
| HY-W067716 |
| (s)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-6-carboxylicacid |
| EN300-242063 |
| (6s)-1h,4h,5h,6h,7h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| EX-A8005D |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " There were no adverse effects upon survival, growth or food intake." | ( Evaluation of the oral toxicity of spinacine hydrochloride in a 13-week study in rats. Allevi, P; Colombo, D; Corsini, E; Galli, CL; Marinelli, P; Orlando, L; Restani, P, 1989) | 0.55 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| alpha-amino acid | An amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 57.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (57.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||